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A B S T R A C T
Purpose: There is growing evidence that complex interactions between seizures and the immune system
shape the course of epilepsy. However, systematic analyses of the effects of antiepileptic drugs (AED) on
the immune system in humans are rare. We performed a prospective study on the inﬂuence of the widely
used AED valproate and levetiracetam on interictal immunological parameters.
Methods: 36 patients were prospectively included. 15 were started on valproate (5 female (33%), age
54  27 years, 12 (80%) on monotherapy), 21 on levetiracetam (10 female (48%), age 45  19 years, 17 (81%)
on monotherapy). Before treatment and after 3 months, we performed a differential blood count and
analyzed the distribution of CD3+CD4+-, CD3+CD8+- and CD4+CD25+-leukocyte subsets using ﬂow cytometry.
In addition, we determined the concentrations of IL-1b, IL-6, TNF-a and MCP-1 in the peripheral blood using
ELISAs.
Results: Valproate intake resulted in a signiﬁcant decrease of the total white blood count (6.96  1.23/nl
vs. 6.13  1.57/nl, p = 0.026) and of absolute count and percentage of neutrophils (4.60  1.05/nl vs.
3.69  1.30/nl, p = 0.01; 65.4  7.9% vs. 59.5  11.5%, p = 0.01, respectively). The percentage of CD3+CD4+-
lymphocytes dropped signiﬁcantly (50.4  10.9% vs. 45.3  12.3%, p = 0.002). Levetiracetam treatment
resulted in a decrease of the percentage of CD4+CD25+-lymphocytes (26.1  8.0% vs. 21.5  9.2%, p = 0.01)
but did not signiﬁcantly alter absolute counts. Neither valproate nor levetiracetam were associated with
signiﬁcant changes in cytokines.
Conclusion: Valproate intake results in profound changes of white blood cell count and subset
distribution. Cytokine levels were not inﬂuenced by valproate or levetiracetam.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
There is growing evidence that epileptic seizures result in
changes of cellular und humoral systemic immunological param-
eters. Vice versa, immunological processes inﬂuence the patho-
genesis and course of epilepsies.1,2Abbreviations: AED, antiepileptic drug; VPA, valproate; LEV, levetiracetam; CD,
cluster of differentiation; IL, interleukin; TNF, tumor necrosis factor; MCP,
monocyte chemoattractant protein; ELISA, enzyme-linked immunosorbent assay;
FACS, ﬂuorescence activated cell scanning; PBS, phosphate-buffered saline; FITC,
ﬂuorescein isothiocyanate; APC, allophycocyanin; PerCP, peridinin chlorophyll; PE,
phycoerythrin; FSC, forward scatter; SSC, side scatter; CCL 2, chemokine (C–C motif)
ligand 2; SD, standard deviation.
* Corresponding author at: University Hospital Munich, Ludwig-Maximilian-
University, Marchioninistr. 15, 81377 Munich, Germany. Tel.: +49 89 4400 73457;
fax: +49 89 4400 78873.
E-mail address: sabina.guenther@med.uni-muenchen.de (S. Guenther).
http://dx.doi.org/10.1016/j.seizure.2014.04.011
1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reIn previous studies, we found increased counts of leukocytes,
neutrophil granulocytes, lymphocytes and NK-cells immediately
after seizures in the peripheral blood of patients with temporal
lobe epilepsy. CD4+ T-lymphocytes dropped which resulted in a
decreased CD4/CD8-ratio.3 IL-6 serum levels increased immedi-
ately postictal and remained elevated for 24 h.4 Interictal
alterations included reduced percentages of B-lymphocytes and
CD4+ T-lymphocytes as well as increased percentages of mono-
cytes.5
The evaluation of interactions between the central nervous
system and immunological processes in epilepsy patients is
complicated by the inﬂuence of antiepileptic drugs (AED) on the
immune system.1 Market authorization studies of levetiracetam
(LEV) showed increased numbers of upper-respiratory tract
infections.6 Valproate (VPA) has various hematologic side effects.7
However, prospective analyses of the effects of AED on the immune
system are rare. Therefore, we analyzed the inﬂuence of VPA andserved.
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epilepsy.
2. Material and methods
2.1. Patients
Between May 2009 and June 2011, we prospectively included
36 patients of our tertiary epilepsy center who were started on
antiepileptic therapy with VPA or LEV. Inclusion criteria were
diagnosis of focal or generalized epilepsy, indication for treatment
with VPA or LEV, continuation of AED intake for at least 6 months
and age above 15 years. All patients provided written informed
consent. The study was approved by the local ethics committee.
Exclusion criteria were malignant brain tumors, acute infections,
other severe neurological or neuroimmunological diseases, inter-
feron or immunoglobulin therapy within the last 6 months,
surgery or signiﬁcant trauma within the last 2 weeks, severe
hepatic or renal insufﬁciency, severe psychiatric disorders and
pregnancy. No other medication with known relevant immuno-
logical effects was started within the study-period.
2.2. Methods and materials
We analyzed leukocytes, neutrophils, lymphocytes and lym-
phocyte subset distribution of CD4+ T-lymphocytes (CD3+CD4+),
CD8+ T-lymphocytes (CD3+CD8+) as well as regulatory T-lympho-
cytes (CD4+CD25+) and levels of IL-1b, IL-6, TNF-a and MCP-1 in
the peripheral blood of the patients.
Before ﬁrst intake of the respective drug, 5 ml EDTA blood for
differential blood count and analysis of lymphocyte subset
distribution and 10 ml serum for cytokine analyses via ELISA
were taken. EDTA blood was processed immediately or stored at
4 8C until processing on the same day. Serum tubes were
centrifuged immediately at 855  g and 4 8C for 15 min and the
serum obtained was stored at 80 8C until further processing.
Differential blood counts were obtained via the central
laboratory of our clinic using standardized methods. Lymphocyte
subsets were analyzed using 4-color ﬂow-cytometry (ﬂuorescence
activated cell scanning (FACS)) as described elsewhere.5 Brieﬂy,
100 ml EDTA blood were mixed 1:1 with phosphate-buffered saline
(PBS) 10% and added to a 96-well microtiter plate. The plates were
centrifuged at 300  g for 4 min and the supernatant was
discarded. For staining 60 ml of CD3-FITC (Beckman Coulter,
Immunotech, France), CD4-APC (Biosciences Pharmingen, USA),
CD8-PerCP (BD Biosciences, USA) and CD25-PE (BD Biosciences,
USA) were mixed with 80 ml PBS 10%. 5 ml were added to each well
and the plate was incubated for 30 min on ice in the dark.
Subsequently, red blood cells were lysed with ammonium chloride
(10%). After washing, both steps were repeated and the remaining
cell pellets were resuspended in 130 ml PBS with 10% fetal calf
serum. Lymphocyte subset analysis was performed using a
FACSCalibur1 and the corresponding CellQuest1 Pro software
(Becton Dickinson). Lymphocytes were analyzed in a lymphocyte
gate resulting from forward scatter- and side scatter-properties.
Relative proportions of leukocyte subsets related to all cells in the
lymphogate and additionally absolute concentrations of the
respective cells were calculated.
Levels of IL-1b, IL-6, TNF-a and MCP-1 were measured using
commercially available ELISA kits (Human IL-1 beta ELISA Ready-
SET-Go!1 and Human CCL2 (MCP-1) ELISA Ready-SET-Go!1,
eBioscience, Germany; PeliKine compactTM human IL-6 ELISA kit
and PeliKine compactTM human TNFa ELISA kit, Sanquin Reagents,
The Netherlands) following manufacturer’s instructions. Sensitivi-
ty levels were 4 pg/ml for IL-1b, 7 pg/ml for MCP-1, 0.2–0.4 pg/ml
for IL-6 and 1–3 pg/ml for TNF-a. If cytokine concentrations werebelow detection thresholds, the missing value was set to the
detection threshold (0.2 pg/ml for IL-1b, 7.8 pg/ml for MCP-1,
0.6 pg/ml for IL-6 and 1.4 pg/ml for TNF-a) to avoid overestimation
of differences between baseline and follow-up values.
After being started on VPA or LEV, we scheduled a follow-up
visit 3 months later and repeated all measurements as described
above.
2.3. Statistics
Categorial variables are given as numbers and percentages,
continuous variables as mean  standard deviation (SD) and
median. Intra-individual comparison of parameters obtained before
ﬁrst drug intake and after 3 months was performed. Because Gaussian
distribution could not be presumed, the non-parametrical Wilcoxon
matched pairs test was used. Statistical analysis was performed using
BiAS fu¨r WindowsTM (Hanns Ackermann, University of Frankfurt,
Germany). P-values < 0.05 were considered statistically signiﬁcant.
Since this study was exploratory, no adjustment for multiple testing
was applied.8
3. Results
36 patients were included. 21 were started on LEV, 15 on VPA.
3.1. Valproate
Within the VPA group (10 male (67%), age 54  27 years (range
15–87)), 12 patients (80%) were treated with VPA in monotherapy.
One patient (7%) was additionally treated with lamotrigine and
topiramate, another patient (7%) with carbamazepine and a third (7%)
with gabapentine. 7 patients (47%) suffered from generalized, 7 (47%)
from focal epilepsies. In one patient (7%), the epilepsy syndrome was
unclassiﬁed. 13 patients (87%) were free of seizures after 3 months of
VPA therapy. The VPA dosage was at this point 903  307 mg/day
(median 900 mg/day).
3.1.1. Leukocytes and cytokines
Due to a technical defect, lymphocyte subset distribution could
not be obtained in two patients at 3 months (n = 13). CD4+CD25+-
levels could not be obtained in another patient (n = 12).
Follow-up values at 3 months showed a signiﬁcant decrease of
the total white blood count from 6.96  1.23/nl to 6.13  1.57/nl
(p = 0.026). Absolute counts of neutrophils decreased from
4.60  1.05/nl to 3.69  1.30/nl (p = 0.01) and the corresponding
percentages from 65.4  7.9% to 59.5  11.5% (p = 0.01).
FACS analysis showed signiﬁcantly lower percentages of
CD3+CD4+-lymphocytes (50.4  10.9% vs. 45.3  12.3%, p = 0.002).
Comparison of cytokine levels did not result in any relevant
differences (Table 1).
3.2. Levetiracetam
11 (52%) of the 21 patients were male (mean age 45  19 years,
range 17–84). 17 patients (81%) received LEV in monotherapy. One
patient (5%) additionally received oxcarbazepine and lamotrigine,
another (5%) carbamazepine and two (10%) lamotrigine. 17 patients
(81%) suffered from focal, 3 (14%) from generalized epilepsy. In one
patient the epilepsy was unclassiﬁed. 10 of 21 patients (48%) were
seizure-free after 3 months. The LEV dosage was at this point
1464  405 mg/day (median 1500 mg/day).
3.2.1. Leukocytes and cytokines
There were no signiﬁcant changes in leukocytes, neutrophils,
total lymphocytes and cytokine levels but the percentage of
Table 1
Valproate patients: differential blood count, FACS analysis of lymphocyte subsets and cytokine concentrations. SD, standard deviation; CI, conﬁdence interval, min,
minimum; max, maximum.
Parameter n Mean SD Median 95% CI min max p
Leukocytes (/nl) Baseline 15 6.96 1.23 6.70 6.10–7.60 5.00 9.27 0.026
Follow-up 15 6.13 1.57 6.00 4.80–7.70 3.20 8.30
Lymphocytes (/nl) Baseline 15 1.78 0.60 1.90 1.40–2.30 0.80 2.90 0.3
Follow-up 15 1.70 0.72 1.70 1.10–2.00 0.50 3.30
Lymphocytes (%) Baseline 15 26.0 8.5 25.9 21.5–33.8 12.5 41.7 0.2
Follow-up 15 28.2 10.8 25.2 18.5–37.7 12.0 46.3
Neutrophils (/nl) Baseline 15 4.60 1.05 4.70 4.00–5.00 2.70 6.50 0.01
Follow-up 15 3.69 1.30 3.60 2.60–4.60 1.80 6.10
Neutrophils (%) Baseline 15 65.4 7.9 67.6 60.3–70.1 48.4 76.2 0.01
Follow-up 15 59.5 11.5 60.6 49.0–69.1 43.7 77.7
CD3+CD8+ (/nl) Baseline 15 0.34 0.23 0.33 0.20–0.46 0.07 1.01 0.6
Follow-up 13 0.34 0.20 0.35 0.19–0.45 0.06 0.84
CD3+CD8+ (%) Baseline 15 17.8 6.8 18.3 14.4–20.4 8.0 34.8 0.9
Follow-up 13 18.1 6.2 17.4 13.8–22.7 6.4 29.9
CD3+CD4+ (/nl) Baseline 15 0.89 0.37 0.90 0.58–1.10 0.35 1.67 0.07
Follow-up 13 0.82 0.50 0.71 0.49–1.09 0.34 2.27
CD3+CD4+ (%) Baseline 15 50.4 10.9 47.0 43.5–59.9 33.8 69.8 0.002
Follow-up 13 45.3 12.3 44.3 34.7–54.3 22.3 68.8
CD4/CD8 Baseline 15 3.45 2.05 2.59 1.86–4.84 1.09 8.10 0.1
Follow-up 13 3.08 2.27 2.73 1.57–3.41 0.98 9.74
CD4+CD25+ (/nl) Baseline 15 0.44 0.16 0.36 0.31–0.57 0.23 0.68 0.1
Follow-up 12 0.37 0.21 0.27 0.21–0.58 0.20 0.83
CD4+CD25+ (%) Baseline 15 27.0 10.9 30.0 15.7–36.8 11.8 43.7 0.1
Follow-up 12 22.4 9.5 21.4 12.8–32.6 8.4 39.7
IL-1b (pg/ml) Baseline 14 2.1 4.6 0.2 0.2–3.3 0.2 17.1 0.4
Follow-up 15 3.6 5.1 0.2 0.2–8.9 0.2 15.5
IL-6 (pg/ml) Baseline 14 2.2 2.1 1.6 0.6–2.9 0.6 8.1 0.3
Follow-up 15 2.7 5.8 0.6 0.6–2.0 0.6 23.4
TNF-a (pg/ml) Baseline 14 25.3 39.3 7.6 1.4–43.5 1.4 144.8 0.9
Follow-up 15 25.1 34.8 18.7 1.4–28.9 1.4 133.7
MCP-1 (pg/ml) Baseline 14 289.7 172.6 217.6 174.2–451.4 100.5 665.9 0.4
Follow-up 15 344.7 312.9 175.2 125.8–591.8 103.7 1215.1
Table 2
Levetiracetam patients: differential blood count, FACS analysis of lymphocyte subsets and cytokine concentrations. SD, standard deviation; CI, conﬁdence interval; min,
minimum; max, maximum.
Parameter n Mean SD Median 95% CI min max p
Leukocytes (/nl) Baseline 21 7.43 1.73 7.20 6.70–8.40 4.40 10.90 0.3
Follow-up 20 6.78 1.74 6.60 5.65–7.61 4.10 10.50
Lymphocytes (/nl) Baseline 20 1.75 0.53 1.75 1.40–1.90 1.10 2.80 0.4
Follow-up 19 1.91 0.71 1.80 1.30–2.30 0.80 3.40
Lymphocytes (%) Baseline 20 23.9 7.7 21.6 18.9–28.9 14.0 39.1 0.2
Follow-up 19 28.0 8.0 29.2 25.7–32.9 10.6 39.3
Neutrophils (/nl) Baseline 18 5.28 1.70 5.00 3.70–6.30 2.80 8.60 0.5
Follow-up 18 4.30 1.26 4.20 3.10–4.90 2.30 6.80
Neutrophils (%) Baseline 18 68.7 8.6 69.1 63.1–75.3 49.2 82.5 0.3
Follow-up 18 63.3 7.5 61.9 57.7–65.5 54.2 81.9
CD3+CD8+ (/nl) Baseline 20 0.35 0.17 0.32 0.28–0.44 0.14 0.77 0.2
Follow-up 19 0.42 0.26 0.41 0.25–0.49 0.10 1.03
CD3+CD8+ (%) Baseline 21 20.3 6.7 20.3 14.6–23.8 10.7 34.9 0.3
Follow-up 21 20.7 7.6 21.2 13.7–25.3 10.1 39.6
CD3+CD4+ (/nl) Baseline 20 0.79 0.31 0.74 0.62–0.83 0.35 1.68 1.0
Follow-up 19 0.81 0.35 0.78 0.60–0.99 0.32 1.54
CD3+CD4+ (%) Baseline 21 45.1 8.1 44.1 39.3–48.9 32.2 62.3 0.5
Follow-up 21 43.4 9.1 42.3 38.9–48.0 21.8 61.1
CD4/CD8 Baseline 21 2.52 1.15 2.15 1.85–2.76 1.04 5.51 0.2
Follow-up 21 2.42 1.17 2.07 1.73–2.49 0.82 5.42
CD4+CD25+ (/nl) Baseline 20 0.45 0.20 0.45 0.32–0.50 0.19 0.96 0.2
Follow-up 19 0.42 0.24 0.31 0.25–0.51 0.10 0.89
CD4+CD25+ (%) Baseline 21 26.1 8.0 27.0 19.7–33.1 12.1 40.9 0.01
Follow-up 21 21.5 9.2 19.1 16.7–28.2 5.3 39.2
IL-1b (pg/ml) Baseline 21 7.0 15.7 0.2 0.2–9.4 0.2 72.1 0.7
Follow-up 21 7.1 12.3 0.2 0.2–9.5 0.2 46.3
IL-6 (pg/ml) Baseline 21 3.4 9.2 0.7 0.6–2.3 0.6 43.4 0.4
Follow-up 21 3.7 6.9 0.6 0.6–2.3 0.6 26.9
TNF-a (pg/ml) Baseline 21 92.3 136.8 40.8 9.6–135.0 1.4 510.0 0.4
Follow-up 21 90.8 117.7 41.3 10.7–131.3 1.4 405.9
MCP-1 (pg/ml) Baseline 21 413.8 337.5 258.3 190.6–545.4 89.0 1172.2 0.09
Follow-up 21 375.4 352.3 240.4 146.5–419.6 78.9 1491.8
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21.5  9.2% (p = 0.01; Table 2).
4. Discussion
Even though hematological side effects of VPA are well-known,
the exact characteristics of these alterations are under discus-
sion.7,9 In this study, VPA treatment induced a signiﬁcant decrease
of the total white blood cell count. Neutrophils were affected most
severely. This effect may in part be due to inhibition of histone
deacetylase by VPA resulting in a disturbed differentiation of
neutrophil progenitors.9,10 Absolute counts of lymphocytes did not
change signiﬁcantly but there was a decrease in the percentage of
CD3+CD4+ T-lymphocytes conﬁrming previous studies.3,11 A
reduced CD4/CD8-ratio has already been described earlier even
though the authors reported additionally increased CD3+CD8+ T-
lymphocytes.11 The clinical relevance of these ﬁndings remains
unclear.
We did not see any relevant changes in leukocytes, neutrophils
or total count of lymphocytes for LEV. Other authors reported
reduced leukocytes in patients on LEV.6 In contrast, Bachmann
et al. found a small but statistically signiﬁcant increase of white
blood cell counts in women on LEV.7 We found a signiﬁcant dip of
the percentage of regulatory CD4+CD25+ T-cells. Absolute cell
counts did not change. As in earlier studies, we did not see
signiﬁcant changes in counts and percentages of CD3+CD4+- or
CD3+CD8+-lymphocytes.5 This result is consistent with the ﬁnding
that LEV does not inﬂuence proliferation or apoptosis of CD3+CD8+
T-lymphocytes.12 Hence, the frequent occurrence of respiratory
infections under LEV treatment does not appear to be caused by
reduced cell numbers. However, LEV might impair the cytotoxic
function of CD3+CD8+ T-lymphocytes by reduction of both perforin
release and CD107a/b expression which might serve as an
alternative explanation of the increased infection rate.12
All cytokines investigated in our study are considered as
possibly causally relevant for development of seizures and
epilepsy.1,2 Thus, inﬂuencing inﬂammatory processes may become
a causal antiepileptic therapy. However, we did not observe
signiﬁcant changes in the examined cytokine blood-levels under
LEV or VPA. For VPA, Somnez et al. saw a signiﬁcant increase of IL-a
in children. They did not observe signiﬁcant changes in the levels of
IL-1b, IL-6 or TNF-a either.13
For all parameters few outliers (i.e. beyond two standard
deviations) were observed, which at least in part accounted for the
wide range of some parameters. Neither a speciﬁc epileptic
syndrome nor intake of one of the drugs was unproportionally
affected. However, in several patients extremes of the data
obtained were obvious for both, baseline and follow-up conditions.
In these patients, aberrant immunological processes with or
without relation to the underlying epileptic syndrome may beresponsible for the outlying parameters rather than changes due to
the antiepileptic drugs.
The study is limited by its relatively small number of
heterogenous patients. 3 patients within the VPA group and 4
patients within the LEV group were treated with at least one
additional AED. Especially lamotrigine and carbamazepine intake
may affect immunological parameters. Even though we did not see
a clear correlation of age and immunological changes, age may
affect immunological parameters.
5. Conclusion
VPA intake resulted in profound changes in white blood cell
count and subset distribution. LEV intake does not inﬂuence counts
of leukocytes or leukocyte subsets. IL-1b, IL-6, TNF-a and MCP-1
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